Your Solutions
BIOMEDTRACKER
Real-time Event Tracking & Drug Development Analysis
管線研發追蹤、獲批前景分析、商業資訊、調研報告
DATAMONITOR HEALTHCARE
Disease Competitive Analysis, 10-20 Years Market Forecast, KOL Insights
疾病競爭分析、10-20年市場預測、KOL專訪
Meet the team
Julie Guan (China)
Head of Strategic Accounts
Citeline
Youmin Zhu (China)
Client Success Manager
Citeline
Training & Help
We provide product training support via online sessions/pre-recorded materials, please click below to access relevant contents, or reach out to this email for any customized training request: [email protected]
我們提供各產品的使用培訓支持，請點擊下列查閲相關培訓資源，若有特定培訓需求或安排則可聯絡：[email protected]
For access or technical issues, please contact your dedicated support team via 'Meet the Team', or contact Client Service team via below email:
若有任何登錄問題，請切換至Meet the Team版面並聯絡對接服務團隊，或可聯絡全球/亞太客服團隊：
Global - [email protected] (English only)
APAC - [email protected] (via English/Chinese)
Require Research Support?
Ask-the-Analyst™
Ask-the-Analyst™
Your status as a loyalty partner includes unlimited access to our highly acclaimed Ask-the-Analyst™ service. With a 24-hour response time, Ask-the-Analyst offers you authoritative information to help you make faster, smarter business decisions.
作爲重點合作夥伴，貴司用戶均可無限量使用「Ask-the-Analyst™」分析師咨詢服務。分析師團隊將會在24小時内回復（工作日），并爲您提供信息收集或專業見解，最終助您做出更快、更明智的業務決策。
Our Ask-the-Analyst team of industry experts leverages the complete suite of pharma intelligence products and publicly available sources to bring you the answers you’re looking for, while your information and all questions received are strictly confidential.
由業界專家組成的Ask the Analyst團隊將結合内部數據與公開領域資源爲您提供相關信息支持，您的個人資訊與提問内容均會被嚴格保密。
Latest Monthly Newsletter
Edition: September 2025
NEWS & INSIGHTS (incl. Key Themes, Latest Interviews, Recent Reg. Guidance)
- Notable Theme (Commercial): US-Japan Tariffs: Informal US confirmation of a 15% tariff for pharma imports from Japan as part of a bilateral trade deal has caused confusion given the apparent lack of official US communication.
- Notable Theme (Commercial): DTC Advertising Impact: The FDA crackdown on DTC advertising raises a new commercial barrier. The industry spent $10.8bn on DTC advertising in the US in 2024, with AbbVie as the leading pharma advertiser.
- Notable Theme (Regulatory): EU Critical Medicines Act: It may include investigational products and mandatory redistribution measures, giving industry a chance to respond before legislation is finalized.
EDITORIAL CONTENTS (incl. Podcasts, Webinars)
- Notable Podcast: China Innovative Drugs And Commercial Insurance
- Notable Webinar: ICH GCP E6(R3): Navigating the New Era of Good Clinical Practice (October 24, 2025)
- Notable Webinar: Cliffhanger: Portfolio Tactics to Scale the $300bn Patent Cliff (October 29, 2025)
DEALS & FINANCING (incl. M&As, Licensing, Financing)
- Notable M&A: Genmab to Acquire Merus for $8B
- Notable Licensing: Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases totalling $5.3B
- Notable Financing: Crystalys Therapeutis Gets $205M in Series A Round
KEY R&D EVENTS (incl. Top-line Readouts, Analyst Commentary, Approval/CRL)
- Notable Analysis: Akeso | Idafang | NSCLC (Phase 3): “HARMONi Update Shows Potential OS Gains in Western Patients but Regulatory Path for Idafang Remains Unclear…”
- Notable Analysis: uniQure | AMT-130 | Huntington's Disease (Phase 2): “AMT-130 emerges as a groundbreaking therapy targeting the root cause of Huntington’s disease with positive results across all clinical endpoints…”
- Notable Analysis: Eli Lilly | Orforglipron | Type-2 Diabetes (Phase 3): “Eli Lilly’s oral non-peptide GLP-1 agonist orforglipron shows superiority to competitor Novo Nordisk’s oral Rybelsus in type 2 diabetes…”
RESEARCH REPORTS (incl. Forecast, Thought Leadership, KOL Interview)
- Notable Report: Key Potential Drug Launches in 2026
- Notable Report: Obesity and GLP-1 Dealmaking: Strategic Trends and Market Signals
- Notable Report: The Annual Clinical Trials Roundup, 2025 Edition: Innovation, Regulation, and Preservation
- Notable Report: The Evolution of Health Literacy: Challenges, Opportunities for Trial Recruitment in the Digital Age
- Notable Report: Working backwards: Patient access strategy is now guiding R&D
- Notable Report: Dealmaking Quarterly Statistics, Q2 2025
- Notable Report: Financing Quarterly Statistics, Q2 2025
- Notable Report: Patient-based Forecast: Obesity
- Notable Report: Epidemiology Forecast: Chronic Urticaria
- Notable Report: Epidemiology & Patient-based Forecast: Sickle Cell Disease
- Notable Report: Epidemiology & Patient-based Forecast: Pancreatic Cancer
- Notable Report: Obesity KOL Interview – US/UK/Germany
- Notable Report: Depression KOL Interview - Germany
Latest Editorial Podcasts
